Shots: The P-III MONALEESA-7 study results involves assessing of Kisqali in combination with endocrine therapy (goserelin + aromatase inhibitor/tamoxifen) vs endocrine therapy as monothx. in pre- and perimenopausal women with […]readmore
Tags : Novartis
Shots: The P-III POLYP 1 & POLYP 2 studies results involve assessing of Xolair (SC, q2w/q4w) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal […]readmore
The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top […]readmore
Shots: Novartis to receive upfront from Sumitomo. Sumitomo to get rights to co-promote Novartis’ Equa and EquMet from July’19 in addition to distribution rights from Nov’19, receiving payment for promotion […]readmore
Shots: The P-III QUARTZ study results involves assessing of QMF149 (150/80 Mu g) vs mometasone furoate (200 Mu g) delivered via Breezhaler & Twisthaler in 802 adult and adolescent patients […]readmore
Regulatory
Novartis’ Zolgensma (onasemnogene abeparvovec-xioi) Receives FDA’s Approval for Spinal Muscular
Shots: The approval is based on ongoing P-III STR1VE & completed P-I START study result assessing Zolgensma (IV) in 21 & 15 patients with SMA and bi-allelic mutation in the […]readmore
Shots: The approval is based on P-III SOLAR-1 study result assessing Piqray (alpelisib) + Fulvestrant vs Fulvestrant in 572 postmenopausal women/men in ratio (1:1) with PIK3CA-mutated HR+/HER2- advanced/m-breast cancer, following […]readmore
Shots: Novartis recalls three lots of Promacta oral suspension to the consumer level due to the presence of peanut floor contamination occurred at third-party manufacturing facility and is conducted within […]readmore
Shots: Takeda to receive $3.4B upfront with 1.9B milestones, making a total deal value of $5.3B. Novartis to get WW rights of Xiidra and will take ~400 employees associated with […]readmore
Shots: The Validation study involves assessing of MSProDiscuss in 198 patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) or a suspected transition to SPMS across the US, Canada & […]readmore